Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Journal of Medicinal Chemistry · 14.09.2023 · 66 (17) · 12559-12585
DOI: 10.1021/acs.jmedchem.3c01186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.08.2023. Verfasst von Zhixiang Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: Receptors, Estrogen, Breast Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, Oncopia Therapeutics, Inc..
Abstract (Originalsprache)
Estrogen receptor α (ERα) is a prime target for the treatment of ER-positive (ER+) breast cancer. Despite the development of several effective therapies targeting ERα signaling, clinical resistance remains a major challenge. In this study, we report the discovery of a new class of potent and orally bioavailable ERα degraders using the PROTAC technology, with ERD-3111 being the most promising compound. ERD-3111 exhibits potent in vitro degradation activity against ERα and demonstrates high oral bioavailability in mice, rats, and dogs. Oral administration of ERD-3111 effectively reduces the levels of wild-type and mutated ERα proteins in tumor tissues. ERD-3111 achieves tumor regression or complete tumor growth inhibition in the parental MCF-7 xenograft model with wild-type ER and two clinically relevant ESR1 mutated models in mice. ERD-3111 is a promising ERα degrader for further extensive evaluations for the treatment of ER+ breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- The Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID-Profile: Biao Hu, Rohan Kalyan Rej, Tianfeng Xu, Duxin Sun, Shaomeng Wang
Förderung
- NCI NIH HHS
- National Cancer Institute
- Oncopia Therapeutics, Inc.
- Proteovant Therapeutics, Inc
Zitieren
APA
Chen, Z., Hu, B., Rej, R. K., Wu, D., Acharyya, R. K., Wang, M., Xu, T., Lu, J., Metwally, H., Wang, Y., McEachern, D., Bai, L., Gersch, C. L., Wang, M., Zhang, W., Li, Q., Wen, B., Sun, D., Rae, J. M., & Wang, S. (2023). Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. Journal of Medicinal Chemistry, 66(17), 12559-12585. https://doi.org/10.1021/acs.jmedchem.3c01186
Vancouver
Chen Z, Hu B, Rej RK, Wu D, Acharyya RK, Wang M, et al. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. Journal of Medicinal Chemistry. 2023;66(17):12559-12585. doi:10.1021/acs.jmedchem.3c01186
BibTeX
@article{Chen2023,
author = {Chen, Zhixiang and Hu, Biao and Rej, Rohan Kalyan and Wu, Dimin and Acharyya, Ranjan Kumar and Wang, Mingliang and Xu, Tianfeng and Lu, Jianfeng and Metwally, Hoda and Wang, Yu and McEachern, Donna and Bai, Longchuan and Gersch, Christina L and Wang, Meilin and Zhang, Wenjing and Li, Qiuxia and Wen, Bo and Sun, Duxin and Rae, James M and Wang, Shaomeng},
title = {Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {17},
pages = {12559--12585},
doi = {10.1021/acs.jmedchem.3c01186}
}
EUVIMED